Source comparison
CJC-1295 vs Unmodified GHRH: Pharmacokinetic Evidence
The clearest differentiator between CJC-1295 and unmodified GHRH (growth hormone-releasing hormone, also known as sermorelin or GHRH 1-29) is plasma half-life. Unmodified GHRH has a half-life of approximately 7 minutes in human plasma due to rapid enzymatic cl
This comparison does not assign a generated winner or score.
- The clearest differentiator between CJC-1295 and unmodified GHRH (growth hormone-releasing hormone, also known as sermorelin or GHRH 1-29) is plasma half-life. Unmodified GHRH has a half-life of approximately 7 minutes in human plasma due to rapid enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV) at the N-terminus. This necessitates multiple daily subcutaneous or intravenous administrations to maintain therapeutic effect. A dosing regimen incompatible with long-duration research protocols or models requiring stable baseline GH elevation.
- CJC-1295 solves this through the DAC modification: a maleimidopropionic acid (MPA) linker conjugated to the peptide backbone binds non-covalently to endogenous serum albumin. Albumin binding dramatically slows renal clearance and enzymatic degradation, extending the terminal half-life to 6–8 days. The 2006 Teichman et al. study demonstrated that a single 30 mcg/kg dose of CJC-1295 sustained IGF-1 elevation above baseline for 7–14 days in healthy adults. A duration 200–300× longer than unmodified GHRH at equivalent molar doses.
- Direct implications for research design: Unmodified GHRH is appropriate for models investigating acute pulsatile GH dynamics, receptor activation kinetics, or short-term interventions (hours to days). CJC-1295 is appropriate for models requiring sustained GH elevation over weeks, chronic metabolic adaptation studies, or protocols where frequent re-dosing introduces confounding stress variables. The pharmacokinetics dictate the application. Using CJC-1295 in a model designed to study episodic GH signaling introduces a design flaw, just as using unmodified GHRH in a 28-day metabolic study creates dosing frequency artifacts that obscure the primary endpoint.